6533b86dfe1ef96bd12c9ff3

RESEARCH PRODUCT

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study.

Sandra Sancho CastilloLorena Franco-martínezJose Luis PlateroAsta TvarijonaviciuteMaría BenllochJesús Escribá-alepuzJosé Enrique De La Rubia Ortí

subject

0301 basic medicineAdultMalemedicine.medical_specialtyepigallocatechin gallateMultiple Sclerosisbeta-hydroxybutyratemuscleinterleukin 6Pilot ProjectsEpigallocatechin gallateMicrobiologyBiochemistryCatechinArticlePathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBeta hydroxybutyrateInternal medicinemedicineHumansIn patientInterleukin 6Muscle SkeletalMolecular Biologybiology3-Hydroxybutyric AcidHaptoglobinsbusiness.industryInterleukin-6Multiple sclerosisHaptoglobinfood and beveragesMiddle Agedmedicine.diseaseQR1-502haptoglobin030104 developmental biologyEndocrinologychemistrybiology.proteinKetone bodiesFemalebusiness030217 neurology & neurosurgeryBiomarkers

description

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment

yearjournalcountryeditionlanguage
2021-04-21Biomolecules
10.3390/biom11050617https://pubmed.ncbi.nlm.nih.gov/33919169